deltatrials
Terminated PHASE2 INTERVENTIONAL 1-arm NCT02934503

Study of Pembrolizumab and Chemotherapy With or Without Radiation in Small Cell Lung Cancer (SCLC)

A Phase II Study of Pembrolizumab and Dynamic PD-L1 Expression in Extensive Stage Small Cell Lung Cancer (SCLC)

Sponsor: Merck Sharp & Dohme LLC

Conditions Small Cell Lung Cancer (SCLC)
Interventions Carboplatin Cisplatin Etoposide Pembrolizumab Radiation therapy
Updated 13 times since 2017 Last updated: Oct 18, 2021 Started: Jan 23, 2017 Primary completion: Oct 1, 2019 Completion: Oct 1, 2019
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

This study was terminated as the standard of care for small cell lung cancer changed in 2018 to include immunotherapy in the front line setting, making this study no longer clinically relevant.

Other terminated trials from Merck Sharp & Dohme LLC

More terminations from Merck Sharp & Dohme LLC

Other Small Cell Lung Cancer (SCLC) trials with similar outcome

Browse all Small Cell Lung Cancer (SCLC) trials

Listed as NCT02934503, this PHASE2 trial focuses on Small Cell Lung Cancer (SCLC) and remains terminated or withdrawn. Sponsored by Merck Sharp & Dohme LLC, it has been updated 13 times since 2017, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Oct 2017 · 8 months · monthly snapshot~Oct 2017 – ~Jun 2018 · 8 months · monthly snapshot~Jun 2018 – ~Oct 2018 · 4 months · monthly snapshot~Oct 2018 – ~Feb 2019 · 4 months · monthly snapshot~Feb 2019 – ~Jun 2019 · 4 months · monthly snapshot~Jun 2019 – ~Sep 2020 · 15 months · monthly snapshot~Sep 2020 – ~Jan 2021 · 4 months · monthly snapshot~Jan 2021 – ~Dec 2021 · 11 months · monthly snapshot~Dec 2021 – ~Jun 2022 · 6 months · monthly snapshot~Jun 2022 – ~Jul 2024 · 25 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 23 months · monthly snapshot

Change History

13 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  3. Jun 2022 — Jul 2024 [monthly]

    Terminated PHASE2

  4. Dec 2021 — Jun 2022 [monthly]

    Terminated PHASE2

    Status: Completed → Terminated

  5. Jan 2021 — Dec 2021 [monthly]

    Completed PHASE2

▶ Show 8 earlier versions

  1. Sep 2020 — Jan 2021 [monthly]

    Completed PHASE2

    Status: Recruiting → Completed

  2. Jun 2019 — Sep 2020 [monthly]

    Recruiting PHASE2

  3. Feb 2019 — Jun 2019 [monthly]

    Recruiting PHASE2

  4. Oct 2018 — Feb 2019 [monthly]

    Recruiting PHASE2

  5. Jun 2018 — Oct 2018 [monthly]

    Recruiting PHASE2

  6. Oct 2017 — Jun 2018 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  7. Feb 2017 — Oct 2017 [monthly]

    Not Yet Recruiting PHASE2

  8. Jan 2017 — Feb 2017 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Merck Sharp & Dohme LLC
  • NYU Langone Health
Data source: NYU Langone Health

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations